SCHEMBL3944332

SCHEMBL3944332

Nc1nc(Cl)cc(-c2ccc(O)cc2Cl)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 10/20 0.71
HSP90AB1 P08238 10/20 0.71
KDM4E B2RXH2 1/20 0.49
PTGS1 P23219 2/20 0.46
PTGS2 P35354 2/20 0.46
ESR1 P03372 6/20 0.45
ESR2 Q92731 5/20 0.45
AGPAT2 O15120 1/20 0.43
CDC7 O00311 1/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
PIM1 P11309 1/20 0.43
PRKACA P17612 1/20 0.43
GRK5 P34947 1/20 0.43
MAP2K2 P36507 1/20 0.43
MAPK8 P45983 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3944846 0.83 HSP90AB1 (1.00) HSP90AA1HSP90AB1KDM4EAGPAT2CDC7
SCHEMBL2849100 0.81 AGPAT2 (0.64) HSP90AA1HSP90AB1KDM4EAGPAT2CDC7
SCHEMBL2849433 0.78 HSP90AA1 (0.60) HSP90AA1HSP90AB1KDM4EAGPAT2CDC7
SCHEMBL15757653 0.77 HSP90AA1 (0.67) HSP90AA1HSP90AB1KDM4EAGPAT2CDC7
SCHEMBL3950560 0.77 HSP90AA1 (1.00) HSP90AA1HSP90AB1KDM4ECDC7DAPK3
SCHEMBL5066591 0.77 NPC1 (0.62) HSP90AA1PTGS1PTGS2ESR1ESR2
SCHEMBL3945098 0.76 HSP90AA1 (1.00) HSP90AA1HSP90AB1KDM4ECDC7CSNK1A1
SCHEMBL6638090 0.75 HSP90AA1 (0.49) HSP90AA1HSP90AB1KDM4EESR1ESR2
SCHEMBL5430298 0.75 HSP90AA1 (0.70) HSP90AA1HSP90AB1KDM4EAGPAT2CDC7
SCHEMBL4282255 0.74 AGPAT2 (0.62) HSP90AA1HSP90AB1KDM4EAGPAT2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885KDM4E 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.